microRNA Replacement Therapy
Press Releases

 
Press Releases
Date Title and Summary View
11-10-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq: MIRN), a biopharmaceutical company focused on microRNA-based oncology therapeutics, today reported financial results for the third quarter of 2016 and provided an update on recent developments. MRX34 CLINICAL PROGRAM ...
09-20-16 Management to host conference call and webcast today at 5 p.m. Eastern AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company, today announced its decision to close the ongoing Phase 1 study of MRX34, its investigational microRNA t...
08-31-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a pipeline of microRNA-based oncology therapeutics, today announced that senior management will participate in two upcoming healthcare investor conferences in September. ...
08-15-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a pipeline of microRNA-based oncology therapeutics, today reported financial results for the second quarter of 2016 and provided an update on recent developments. ...
07-05-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced that President and Chief Executive Officer Paul Lammers, M.D., M.Sc., will present a corporate overview ...
06-30-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the appointment of Perry Nisen, M.D., Ph.D., to the Company's Board of Directors. Dr. Nisen currently se...
06-06-16 Oral presentation highlights safety profile of MRX34, microRNA target engagement, and multiple clinical responses in cancer patients CHICAGO--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq: MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based ...
05-12-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today reported financial results for the first quarter of 2016 and provided an update on recent developments. ...
04-25-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the appointment of Vincent J. O'Neill, M.D., B.Sc., M.R.C.P. as Chief Medical Officer, effective April 2...
04-20-16 Results reported in two poster presentations suggest MRX34 combination regimens may enhance effectiveness of standard cancer therapies AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of m...
Page:
1
... NextLast
= add release to Briefcase
© 2017 Mirna Therapeutics, Inc. All Rights Reserved.